APGE Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

133.870

Open

133.300

VWAP

133.56

Vol

1.05M

Mkt Cap

10.04B

Low

133.270

Amount

140.78M

EV/EBITDA(TTM)

Total Shares

75.18M

8.98B

EV/OCF(TTM)

P/S(TTM)

Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Ra. APG279 is for the dual inhibition of OX40L and IL-13.

Events Timeline

(ET)

2026-06-24

10:01:00

Stifel Downgrades Apogee Therapeutics to Hold with Price Target of $135

2026-06-23 (ET)

2026-06-23

08:30:00

RBC Raises Apogee Price Target to $135

2026-06-23

08:30:00

Guggenheim Downgrades Apogee Therapeutics to Neutral

2026-06-23

07:30:00

BofA Moves to No Rating on Apogee Therapeutics After AbbVie Acquisition

2026-06-23

07:00:00

RBC Downgrades Apogee to Sector Perform, Raises Price Target to $135

News

8.5

07-07Fool

iShares Core High Dividend ETF Outperforms S&P 500

8.5

07-07NASDAQ.COM

iShares Core High Dividend ETF Surges Over 15% Year-to-Date

8.5

07-07PRnewswire

Investor Rights Law Firm Investigates Multiple Companies

7.0

07-02PRnewswire

Investor Rights Law Firm Investigates Multiple Companies for Potential Violations

4.5

07-02NASDAQ.COM

Analysis of XBI ETF's 52-Week Price Fluctuations

7.0

07-02Globenewswire

Ademi LLP Investigates Apogee for Possible Violations

15 Analyst Rating

Wall Street analysts forecast APGE stock price to rise

13 Buy

2 Hold

0 Sell

Strong Buy

Current: 0.000

Low

83.00

Averages

105.67

High

137.00

Current: 0.000

Low

83.00

Averages

105.67

High

137.00

Mizuho

Joseph Catanzaro

Outperform

Neutral

downgrade

$110 -> $135

AI Analysis

2026-06-24

Reason

Mizuho

Joseph Catanzaro

Price Target

$110 -> $135

AI Analysis

2026-06-24

downgrade

Outperform

Neutral

Reason

Mizuho analyst Joseph Catanzaro downgraded Apogee Therapeutics to Neutral from Outperform with a price target of $135, up from $110, after the company entered into an agreement to be acquired by AbbVie for $135.11 per share in cash or $10.9B. The firm expects the deal to close.

TD Cowen

Buy

Hold

downgrade

$NULL

2026-06-23

Reason

TD Cowen

Price Target

$NULL

2026-06-23

downgrade

Buy

Hold

Reason

TD Cowen downgraded Apogee Therapeutics (APGE) to Hold from Buy with no price target. The firm said it is \"sad to see Apogee go,\" but the timing post critical Phase II data and pre Phase III initiation is an ideal window, and the $10.9B valuation looks reasonable. AbbVie (ABBV) has the infrastructure to execute the atopic dermatitis Phase III expeditiously and to expand rapidly into additional indications, the analyst tells investors in a research note. The firm added it assumes the process was robust and expects it to close in Q3, and is therefore downgrading to Hold.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for APGE

Unlock Now

Valuation Metrics

The current forward P/E ratio for Apogee Therapeutics Inc (APGE.O) is 0.00, compared to its 5-year average forward P/E of -12.33. For a more detailed relative valuation and DCF analysis to assess Apogee Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-12.33

Current PE

0.00

Overvalued PE

-7.92

Undervalued PE

-16.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6.72

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-2.10

Undervalued EV/EBITDA

-11.34

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

206.46

Current PS

799.41

Overvalued PS

682.21

Undervalued PS

-269.28

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

suggest short term stocks for this week

Intellectia · 37 candidates

Market Cap: >= 5.00BRegion: USPrice: $15.00 - $120.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Week Price Change Pct: $4.00 - $25.00Monthly Average Dollar Volume: >= 2,000,000

Ticker

Name

Market Cap$

Unity Software Inc

8.42B

Alcoa Corp

15.41B

CHWY

Chewy Inc

10.88B

DOW

Dow Inc

29.29B

SMMT

Summit Therapeutics Inc

12.86B

LYB

LyondellBasell Industries NV

25.92B

stock of the day march 26th Thursday 2026

Intellectia · 19 candidates

Market Cap: >= 5.00BRegion: USPrice: $10.00 - $300.00Price Change Pct: $5.00 - $20.00List Exchange: XNYS, XNAS, XASENews Driver: Positive

Ticker

Name

Market Cap$

INTC

Intel Corp

236.53B

TERN

Terns Pharmaceuticals Inc

5.75B

AMD

Advanced Micro Devices Inc

359.13B

CIFR

Cipher Digital Inc

6.43B

RKLB

Rocket Lab Corp

41.50B

ARM

Arm Holdings PLC

166.81B

What stocks have a new buy signal today?

Intellectia · 55 candidates

Market Cap: >= 5.00BRegion: USMarket Cap Category: large, mega, midPrice Change Pct: >= $4.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceCrossAboveMA20, PriceAboveMA200

Ticker

Name

Market Cap$

ARM

Arm Holdings PLC

143.33B

SMMT

Summit Therapeutics Inc

12.05B

CHWY

Chewy Inc

9.73B

Planet Labs PBC

11.02B

ASTS

AST SpaceMobile Inc

33.23B

RKLB

Rocket Lab Corp

37.62B

which stocks have high short float

Intellectia · 65 candidates

Market Cap: >= 5.00BRegion: USPrice: >= $10.00Short Ratio: MoreThan30PctList Exchange: XNYS, XNAS, XASEIs Optionable: TrueMonthly Average Dollar Volume: >= 2,000,000

Ticker

Name

Market Cap$

WSO

Watsco Inc

15.96B

WYNN

Wynn Resorts Ltd

10.60B

NEU

NewMarket Corp

6.03B

PRAX

Praxis Precision Medicines Inc

8.65B

MEDP

Medpace Holdings Inc

13.36B

KRYS

Krystal Biotech Inc

7.42B

Whales Holding APGE

Fairmount Funds Management LLC

Paradigm Biocapital Advisors LP

Driehaus Capital Management LLC

Sofinnova Investments, Inc.

Avoro Capital Advisors LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Apogee Therapeutics Inc (APGE) stock price today?

The current price of APGE is 133.54 USD — it has increased 0.03

What is Apogee Therapeutics Inc (APGE)'s business?

What is the price predicton of APGE Stock?

Wall Street analysts forecast APGE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APGE is105.67 USD with a low forecast of 83.00 USD and a high forecast of 137.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.